NovoCure, Ltd., a medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round.
Investors in this round of financing included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.
As stated by William Doyle, Chairman of the Board of the Isle of Jersey and Haifa, Israel-based company, the proceeds will be used to fund NovoCure’s newly-diagnosed GBM pivotal clinical trial.
FinSMEs
28/09/2009